Abstract: Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.

Abstract: In some embodiments, the camera system comprises: an optical assembly to create an optical image from the optical wavefront; a deformable phase plate (DPP) to receive the optical image from the optical assembly and to adjust the optical image in accordance with a control signal, the DPP including a deformable surface suspended over a cavity filled with optical fluid, and electrical actuation elements configured to change a shape of the deformable surface based on the control signal, the electrical actuation elements arranged in a pattern in the cavity and, when activated, provide an electrostatic force on the deformable surface; an image sensor to convert the adjusted optical image into electrical signals; an image signal processor to generate a digital image from the electrical signals; and an estimator to estimate an aberration or tilt correction of the digital image and to generate the control signal based on the estimated aberration or tilt correction.

Abstract: Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-?)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17?-ol-3-one esters that comprise (17-?)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-?)-3-oxoandrost-4-en-17-yl undecanoate, (17-?)-3-oxoandrost-4-en-dodecanoate, and (17-?)-3-oxoandrost-4-en-17-yl tridecanoate. A single oral administration to a male subject of one or more dosage forms with a total androst-4-en-17?-ol-3-one equivalent dose of about 150 mg to about 895 mg is provided. In another embodiment, a method for providing a serum concentration of androst-4-en-17?-ol-3-one within a target PK performance for a male subject is provided.

Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one. Pharmaceutical compositions and the dosage forms of the bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters can be used to treat any condition associated with testosterone deficiency, including complete absence of endogenous testosterone in male or female subjects.

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

Abstract: Disclosed is a method and composition for treating CNS disorders in a subject. In an embodiment, the method preferably comprises the ordered steps of identifying a subject having or being predisposed to epilepsy, and orally administering to the subject an AED. The administration preferably comprises an administration regimen of a predetermined quantity of the AED, at a predetermined frequency, and for a predetermined duration. The subject preferably comprises a subject experiencing seizure clusters, WWE, and more especially a WWE of childbearing age. The composition preferably comprises a NAS, and more especially an ENAS. The method preferably results in the prevention, or reduced frequency or magnitude of epileptic seizures.

Abstract: Systems, apparatuses, and methods for controlling bandwidth through shared transaction limits are described. An apparatus includes at least a plurality of agents, a plurality of transaction-limit (T-Limit) nodes, a T-Limit manager, and one or more endpoints. The T-Limit manager creates a plurality of credits for the plurality of agents to send transactions to a given endpoint. Then, the T-Limit manager partitions the credits into N+1 portions for N agents, wherein the extra N+1 portion is a shared pool for use by agents when they run out of their private credits. The T-Limit manager assigns a separate private portion of the N portions to the N agents for use by only the corresponding agent. When an agent runs out of private credits, the agent's T-Limit node sends a request to the T-Limit manager for credits from the shared pool.

Abstract: Disclosed are methods and oral compositions for treating CNS disorders. An embodiment of the invention comprises orally administering a 3?-OH-5?-pregnan-20-one containing composition to a subject having a CNS disorder. The composition preferably exhibits a fast release rate of the 3?-OH-5?-pregnan-20-one. The current compositions may provide desired serum levels of 3?-OH-5?-pregnan-20-one to effectively treat CNS disorders. The oral compositions and methods disclosed herein may be administered to a subject in need of CNS disorder therapy, to deliver therapeutically effective amounts of 3?-OH-5?-pregnan-20-one for treating CNS disorders.

Abstract: A system and method for efficiently arbitrating traffic on a bus. A computing system includes a fabric for routing traffic among one or more agents and one or more endpoints. The fabric includes multiple arbiters in an arbitration hierarchy. Arbiters store traffic in buffers with each buffer associated with a particular traffic type and a source of the traffic. Arbiters maintain a respective urgency counter for keeping track of a period of time traffic of a particular type is blocked by upstream arbiters. When the block is removed, the traffic of the particular type has priority for selection based on the urgency counter. When arbiters receive feedback from downstream arbiters or sources, the arbiters adjust selection priority accordingly. For example, changes in bandwidth requirement, low latency tolerance and active status cause adjustments in selection priority of stored requests.

Abstract: A head-mounted device may have lenses. A user may view images through the lenses from eye boxes. The lenses may be tunable liquid lenses. Each lens may have a lens chamber. The lens chamber of the lens may have rigid and/or flexible walls that form optical lens surfaces. Actuators and/or pump and reservoir systems may deform the lens surfaces in response to control signals from a control circuit to tune the lens. Each liquid lens may have oil or other liquid in the lens chamber for that lens. Inorganic dielectric particles or other refractive-index-adjustment particles may be used to adjust the refractive index of the lens. The particles may be subwavelength in size.

Abstract: Described here are substantially pure (17-?)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof.

Abstract: Disclosed are methods and compositions for testosterone replacement therapy, especially for use in administration to hypogonadal males. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a non-undecanoate testosterone ester while avoiding unacceptably high testosterone levels.

Abstract: Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-?)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17?-ol-3-one esters that comprise (17-?)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-?)-3-oxoandrost-4-en-17-yl undecanoate, (17-?)-3-oxoandrost-4-en-dodecanoate, and (17-?)-3-oxoandrost-4-en-17-yl tridecanoate. A single oral administration to a male subject of one or more dosage forms with a total androst-4-en-17?-ol-3-one equivalent dose of about 150 mg to about 895 mg is provided. In another embodiment, a method for providing a serum concentration of androst-4-en-17?-ol-3-one within a target PK performance for a male subject is provided.

Abstract: An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester while avoiding unacceptably high testosterone levels.

Abstract: Apparatus for deflection of a beam of light includes a case, which is configured to be positioned in a path of the beam, and a liquid, which is contained within the case. An array of plates is disposed across a surface of the liquid. The plates are configured to rotate on the surface about respective axes, which are mutually parallel and are spaced apart by a predefined pitch. An actuator is configured to drive a rotation of the plates about the respective axes so as deflect the beam that is incident on the plates.

Abstract: Systems, apparatuses, and methods for controlling bandwidth through shared transaction limits are described. An apparatus includes at least a plurality of agents, a plurality of transaction-limit (T-Limit) nodes, a T-Limit manager, and one or more endpoints. The T-Limit manager creates a plurality of credits for the plurality of agents to send transactions to a given endpoint. Then, the T-Limit manager partitions the credits into N+1 portions for N agents, wherein the extra N+1 portion is a shared pool for use by agents when they run out of their private credits. The T-Limit manager assigns a separate private portion of the N portions to the N agents for use by only the corresponding agent. When an agent runs out of private credits, the agent's T-Limit node sends a request to the T-Limit manager for credits from the shared pool.

Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.

Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.